Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Growth Hormone Deficiency in Adults - Treatment & Management
Linus Pauling Institute Oregon State University Reviewed in August 2024 by: Maret G
Gobron B, Couchot M, Irwin N, Legrand E, Bouvard B, Mabilleau G
Results Summary of basic information of existing GLP-1RA in China As of December 2023, there were 9 drugs in the GLP-1RA class approved for the treatment of T2DM in China, including Semaglutide injection, Liraglutide injection, Dulaglutide injection, Polyethylene glycol loxenatide injection, Insulin degludec and liraglutide injection, Exenatide injection, Benaglutide injection, Exenatide microsphees for injection, and Lixisenatide injection [21, 22]
The effects of GLP-1 RAs on gastrointestinal motility have important clinical implications, including possible increased periprocedural aspiration risk and potential challenges with medication adherence and tolerability
This is the "double-hit" that catches many people off guard
